A Nanogel with Effective Blood-Brain Barrier Penetration Ability through Passive and Active Dual-Targeting Function
Open Access
- 24 December 2021
- journal article
- research article
- Published by Wiley in Journal of Nanomaterials
- Vol. 2021, 1-11
Abstract
Clinically, surgery assisted by chemotherapy is the most effective treatment of cancer. But from our clinical observation, the median survival of patients with glioblastoma is still not so good with only 15-16 months. The low therapeutic index is mainly due to the blood-brain barrier (BBB) which significantly hindered the chemotherapeutic drug accumulation in tumor tissue. One main composition of the BBB is astrocyte, which contains a lipophilic cell membrane, which prevents more than 98 of small-molecule drugs from entering the brain. Previously, we found that the nanogel with passive targeting function can increase the BBB penetration ability, which indicates that it could be used to overcome the above mentioned in vivo obstacles which promoted drug accumulation in the tumor. In this study, thermosensitive targeted nanogel delivery systems (DPPC) with cell-penetrating peptides (CPP) are introduced onto the particle surface for active astrocyte breaking. The hydrodynamic radius of DPPC is around 300nm, the potential is about 0-5mV, and the TEM and DLS studies further confirm its well spherical morphology and uniform distribution. The DPPC is verified as the biocompatible carriers for further application by cell viability tests. The in vitro-constructed BBB model successfully proves that DPPC can efficiently penetrate the BBB, which is attributed to both the temperature-sensitive passive targeting and the active CPP penetration. Consequently, the intracellular doxorubicin (DOX) promotes such functional DPPC at the relatively high temperature inside tumor microenvironment (TME) (42C), which obviously improves intratumor drug accumulation and tumor cell-killing effects. The dual-targeted nanogel delivery systems designed in this study provides a more effective strategy for the treatment of glioma.Keywords
Funding Information
- Naval Medical University (2018QN0003, 2018ZX09J18107-4, 92059112, 81802714)
- National Key New Drug Creation and Manufacturing Program, Ministry of Science and Technology (2018QN0003, 2018ZX09J18107-4, 92059112, 81802714)
- National Natural Science Foundation of China (2018QN0003, 2018ZX09J18107-4, 92059112, 81802714)
This publication has 46 references indexed in Scilit:
- Effect of block compositions of amphiphilic block copolymers on the physicochemical properties of polymeric micellesPolymer, 2011
- Structure and function of the blood–brain barrierNeurobiology of Disease, 2010
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialThe Lancet Oncology, 2009
- Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood–brain barrier (BBB)European Journal of Pharmaceutics and Biopharmaceutics, 2009
- Who Classification of Tumours of the Central Nervous System (4th edition)Neuropathology and Applied Neurobiology, 2007
- Genetic Pathways to Primary and Secondary GlioblastomaThe American Journal of Pathology, 2007
- The Blood-Brain Barrier/Neurovascular Unit in Health and DiseasePharmacological Reviews, 2005
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- The blood–brain barrier: an overviewNeurobiology of Disease, 2004
- CNS midline anomalies in the opitz G/BBB syndrome: Report on 12 Brazilian patientsAmerican Journal of Medical Genetics, 1992